A 52-year-old man with acute myocardial infarction presents to the ICU with systolic blood pressure of 85 mmHg, heart rate 110/min, cold extremities, and oliguria. Pulmonary artery catheter shows PCWP 18 mmHg and cardiac index 1.8 L/min/m². After fluid resuscitation, persistent cardiogenic shock remains. Which is the drug of choice for initial inotropic support?

Explanation

## Cardiogenic Shock: Initial Inotropic Support **Key Point:** Dobutamine is the drug of choice for initial inotropic support in cardiogenic shock when systolic blood pressure is ≥80–90 mmHg after fluid resuscitation, as in this patient (SBP 85 mmHg post-resuscitation with low cardiac index). ### Why Dobutamine? Dobutamine is a synthetic catecholamine with predominantly **β₁-adrenergic** agonist activity: | Property | Effect | |---|---| | β₁ stimulation | ↑ Contractility (inotropy), ↑ cardiac output | | Mild β₂ stimulation | Modest peripheral vasodilation (↓ afterload) | | Minimal α effect | No significant vasoconstriction | **High-Yield:** In cardiogenic shock with: - Low cardiac index (CI < 2.2 L/min/m²) → needs inotropic support - Elevated PCWP (≥18 mmHg) → adequate/elevated preload, no more fluid - SBP ≥ 80–90 mmHg → dobutamine is preferred over dopamine Dobutamine at **2–20 µg/kg/min** improves cardiac output and reduces filling pressures (PCWP), making it ideal for this hemodynamic profile. ### Current Guideline Position **Clinical Pearl:** Per **Harrison's Principles of Internal Medicine (21e)** and **ACC/AHA Heart Failure Guidelines**, dobutamine is the preferred initial inotrope in cardiogenic shock when blood pressure is not severely compromised. Dopamine is reserved for more profoundly hypotensive states (SBP < 80 mmHg) where its vasopressor (α-adrenergic) effect is needed to maintain perfusion pressure. The SOAP II trial (De Backer et al., NEJM 2010) demonstrated that dopamine was associated with **more arrhythmias** and a trend toward higher mortality in cardiogenic shock compared to norepinephrine/dobutamine combinations, further supporting dobutamine as the preferred inotrope. ### Why Not the Other Options? - **Dopamine (B):** Dose-dependent effects include tachycardia and arrhythmias; preferred only when SBP < 80 mmHg or when vasopressor effect is needed alongside inotropy. This patient's SBP of 85 mmHg post-resuscitation makes dobutamine more appropriate. - **Epinephrine (A):** Reserved for **refractory** cardiogenic shock; excessive α-adrenergic stimulation increases afterload and myocardial oxygen demand, worsening ischemia in acute MI. - **Milrinone (D):** Phosphodiesterase-3 inhibitor with inotropic + vasodilatory properties; **contraindicated in hypotensive shock** as it causes systemic vasodilation and can precipitate further hypotension. Reserved for euvolemic or hypertensive heart failure with reduced EF. ### This Patient's Hemodynamic Profile | Parameter | Value | Interpretation | |---|---|---| | SBP | 85 mmHg | Hypotensive but not severely so (≥80 mmHg) | | Cardiac Index | 1.8 L/min/m² | Low (normal >2.2) → needs inotrope | | PCWP | 18 mmHg | Elevated → preload adequate, no more fluid | **Dobutamine** at 2–10 µg/kg/min is the correct initial inotropic agent in this scenario. [cite: Harrison 21e Ch 252; ACC/AHA 2022 Heart Failure Guidelines; De Backer et al. NEJM 2010]